{
    "id": "e94c0cff-48b4-4cb6-b7db-86013d3cf2c7",
    "indications": "brekiya indicated acute treatment migraine without aura acute treatment cluster headaches adults . limitations brekiya indicated preventive treatment migraine . brekiya indicated management hemiplegic migraine migraine brainstem aura .",
    "contraindications": "subcutaneous injection . ( 2.1 ) recommended 1 mg administered subcutaneously single 1 ml autoinjector . ( 2.1 ) exceed 3 mg ( 3 doses ) 24-hour period . ( 2.1 ) exceed 6 mg ( 6 doses ) week . ( 2.1 ) prior initiation , cardiovascular evaluation recommended . ( 2.2 )",
    "adverseReactions": "brekiya contraindicated patients : concomitant strong cyp3a4 inhibitors [ ( 5.1 ) ( 7.1 ) ] ischemic heart disease ( e.g . , angina pectoris , history myocardial infarction , documented silent ischemia ) patients symptoms findings consistent coronary artery vasospasm , including prinzmetal 's variant angina [ ( 5.4 ) ] uncontrolled hypertension [ ( 5.5 ) ] peripheral arterial disease sepsis following vascular surgery severe hepatic impairment severe renal impairment known hypersensitivity dihydroergotamine , ergot alkaloids , latex , ingredients brekiya [ ( 5.9 ) ] recent ( i.e . , within 24 hours ) 5-ht1 agonists , ergotamine-containing ergot-type medications [ ( 7.2 ) ] concomitant peripheral central vasoconstrictors combination may result additive synergistic elevation blood pressure [ ( 5.5 ) ]",
    "ingredients": [
        {
            "name": "DIHYDROERGOTAMINE MESYLATE",
            "code": "81AXN7R2QT"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "METHANESULFONIC ACID",
            "code": "12EH9M7279"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "organization": "Amneal Pharmaceuticals LLC",
    "name": "BREKIYA",
    "effectiveTime": "20250515",
    "indications_original": "BREKIYA is indicated for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.\n                  \n                      \n                  \n                  \n                     Limitations of Use \n                  \n                  BREKIYA is not indicated for the preventive treatment of migraine. \n                  BREKIYA is not indicated for the management of hemiplegic migraine or migraine with brainstem aura.",
    "contraindications_original": "For subcutaneous injection only. ( 2.1 ) Recommended dosage is 1 mg administered subcutaneously as a single 1 mL autoinjector. ( 2.1 ) Do not exceed 3 mg (3 doses) in a 24-hour period. ( 2.1 ) Do not exceed 6 mg (6 doses) in a week. ( 2.1 ) Prior to initiation, a cardiovascular evaluation is recommended. ( 2.2 )",
    "adverseReactions_original": "BREKIYA is contraindicated in patients:\n                  \n                     with concomitant use of strong CYP3A4 inhibitors [see Warnings and Precautions (5.1) and Drug Interactions (7.1)]\n                     \n                     with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina [see Warnings and Precautions (5.4)]\n                     \n                     with uncontrolled hypertension [see Warnings and Precautions (5.5)]\n                     \n                     with peripheral arterial disease \n                     with sepsis \n                     following vascular surgery \n                     with severe hepatic impairment \n                     with severe renal impairment\n                     with known hypersensitivity to dihydroergotamine, ergot alkaloids, latex, or any of the ingredients in BREKIYA [see Warnings and Precautions (5.9)]\n                     \n                     with recent use (i.e., within 24 hours) of other 5-HT1 agonists, ergotamine-containing or ergot-type medications [see Drug Interactions (7.2)]\n                     \n                     with concomitant use of peripheral and central vasoconstrictors because the combination may result in additive or synergistic elevation of blood pressure [see Warnings and Precautions (5.5)]"
}